Notch/Delta-Jagged Signaling: NICD Proteolytic Release, CSL Transcriptional Switch, and Vascular Specification

# Notch/Delta-Jagged Signaling: NICD Proteolytic Release, CSL Transcriptional Switch, and Vascular Specification

Research Use Only (RUO) — Not for Human or Animal Therapeutic Use

The Notch signaling pathway is a juxtacrine cell communication system in which ligand and receptor are both membrane-bound, requiring direct cell-cell contact for signal initiation. This contact-dependent architecture enables the precise spatial patterning programs that Notch governs: lateral inhibition in neural progenitor commitment, inductive specification in vascular arterial-venous identity, intestinal secretory vs. absorptive fate decisions, and T-cell lineage allocation in the thymus. The pathway's central mechanism — regulated intramembrane proteolysis releasing the Notch intracellular domain (NICD) for nuclear translocation — is executed by two sequential cleavage events: ADAM metalloprotease (S2 cleavage) followed by the γ-secretase complex (S3 cleavage). NICD then displaces a co-repressor from the CSL/RBPJ transcription factor, converting it from a repressor to an activator of HES and HEY target genes. Pharmacological control of this proteolytic cascade using γ-secretase inhibitors (DAPT, DBZ, LY411575) has enabled systematic dissection of Notch biology across developmental and disease contexts.

Notch Receptor Family: Architecture and Structural Organization

Four Mammalian Notch Paralogues

Mammals express four Notch receptors (NOTCH1–4), each a single-pass type I transmembrane protein of 270–300 kDa. The overall domain architecture is conserved: a large extracellular domain (ECD) composed primarily of epidermal growth factor-like (EGF-like) repeats, a negative regulatory region (NRR) containing Lin12-Notch repeats (LNR) and a heterodimerization domain (HD), a transmembrane helix, a RAM domain, ankyrin repeats (ANK), a transcriptional activation domain (TAD), and a PEST degradation sequence.

EGF-like repeats: Notch1 contains 36 EGF-like repeats in its extracellular domain. EGF repeats 11–12 constitute the primary ligand binding site for both Delta-like and Jagged ligands. O-fucosylation at the consensus sequence C²XXGG(S/T)C³ within specific EGF repeats, catalyzed by POFUT1 (protein O-fucosyltransferase 1) in the ER, is essential for Notch ligand recognition and surface expression. FRINGE glycosyltransferases (Lunatic, Manic, Radical Fringe) extend the O-fucose monosaccharide into a disaccharide (Fuc-GlcNAc), preferentially enhancing Notch binding to Delta-like ligands while reducing Jagged binding affinity — a key mechanism for context-dependent ligand selectivity in Notch signaling.

Negative regulatory region (NRR): The NRR, comprising three LNR modules and the HD domain, maintains Notch in an autoinhibited conformation in the absence of ligand. The three LNR modules (each ~35 aa with three disulfide bonds) clamp over the S2 cleavage site, preventing ADAM protease access. Crystal structures of the Notch NRR (Gordon et al., 2007) revealed that this autoinhibition is an allosteric mechanism — ligand engagement of EGF11-12 is thought to transmit mechanical force through the EGF repeat array to destabilize the NRR, exposing the ADAM protease cleavage site.

Furin processing and heterodimerization: Notch receptors undergo constitutive S1 cleavage by furin-family proprotein convertases in the trans-Golgi network, generating an ECD fragment and a membrane-tethered intracellular fragment. These two fragments reassemble at the HD domain via non-covalent interactions, forming the mature heterodimeric Notch receptor displayed at the cell surface. The S1 site is within the HD domain; HD domain mutations that stabilize the ECD-TM heterodimer (e.g., in the NICD-generating T-ALL mutations L1601P) constitute gain-of-function Notch1 alleles.

Delta-like and Jagged Ligands

DSL Domain Ligands: Five Mammalian Paralogues

Mammals express five canonical Notch ligands: Delta-like 1 (DLL1), Delta-like 3 (DLL3), Delta-like 4 (DLL4), Jagged1 (JAG1), and Jagged2 (JAG2). All contain an N-terminal DSL (Delta-Serrate-Lag2) domain and multiple EGF-like repeats as the receptor-binding module, a single transmembrane helix, and a short cytoplasmic tail. Jagged ligands additionally possess a cysteine-rich domain (CRD) adjacent to the EGF repeat array that is absent from Delta-like ligands — a structural feature correlated with their distinct signaling properties and FRINGE sensitivity.

DLL4 in vascular biology: DLL4 is expressed specifically on arterial endothelium and tip cells during angiogenesis, making it the key Notch ligand in vascular patterning. DLL4 on tip cells activates Notch1 on adjacent stalk cells, suppressing VEGFR2 and neuropilin-1 expression and preventing stalk cells from adopting tip cell identity — the lateral inhibition mechanism that controls tip/stalk cell ratio and vessel branching morphogenesis (Hellström et al., 2007).

JAG1 and arterial specification: JAG1 is expressed on arterial endothelium and vascular smooth muscle cells. JAG1/Notch3 signaling maintains smooth muscle arterial identity, while JAG1/Notch1 in endothelium cooperates with DLL4/Notch for arterial specification. Haploinsufficiency of JAG1 causes Alagille syndrome — characterized by bile duct paucity, cardiac defects, and vertebral anomalies — establishing JAG1 as a critical developmental Notch ligand in multiple organ systems.

Ligand Endocytosis and Signal Sending

An unexpected feature of Notch ligand biology is that ligand endocytosis in the signal-sending cell is required for productive Notch activation in the signal-receiving cell. Epsin-dependent endocytosis of ubiquitinated DSL ligands (ubiquitinated by Neuralized/NEUR and Mindbomb/MIB E3 ligases) generates mechanical force on the receptor ECD — the "pulling force" model — that destabilizes the NRR and enables ADAM protease access (Meloty-Kapella et al., 2012). Mindbomb1 (MIB1) is the dominant mammalian E3 ligase for DLL1, DLL4, and JAG1; MIB1 deletion phenocopies complete Notch pathway loss in mouse embryos.

Proteolytic Activation: S2 and S3 Cleavages

S2 Cleavage: ADAM10 (and ADAM17)

Following ligand binding and NRR destabilization, the membrane-proximal S2 site in the Notch ECD becomes accessible to ADAM metalloprotease cleavage. ADAM10 (a disintegrin and metalloprotease 10, also known as Kuzbanian in Drosophila) is the primary sheddase for Notch S2 cleavage in most developmental contexts; ADAM17 (TACE/ADAM17) can perform S2 cleavage at higher activity levels and is particularly relevant in pathological Notch activation (ligand-independent shedding under inflammatory conditions). S2 cleavage occurs at the Val1744-Leu1745 bond (Notch1 numbering), releasing the Notch ECD as a soluble fragment and generating the membrane-tethered Notch extracellular truncation (NEXT) intermediate.

ADAM10 substrate specificity for Notch requires the disintegrin domain of ADAM10 to engage Notch EGF-like repeats proximal to the NRR — a substrate docking interaction distinct from simple active-site access. ADAM10 null embryos die at E9.5 with severe somitogenesis and neurogenesis defects that phenocopy complete Notch loss, confirming ADAM10 as the essential S2 sheddase (Hartmann et al., 2002).

S3/S4 Cleavage: The γ-Secretase Complex

The NEXT intermediate (membrane-tethered Notch without ECD) is then cleaved within the transmembrane helix by the γ-secretase complex — a multi-subunit intramembrane aspartyl protease complex. The four obligate γ-secretase components are:

Presenilin 1 or 2 (PSEN1/2): The catalytic subunit containing two catalytic aspartate residues (D257 and D385 in PSEN1) within transmembrane domains 6 and 7. Presenilin undergoes endoproteolytic autocleavage generating N-terminal and C-terminal fragments that together form the active aspartyl protease site.

Nicastrin (NCSTN): A type I transmembrane glycoprotein that functions as a substrate receptor — its ectodomain glutamate (E333) binds the free N-terminus of single-pass transmembrane stubs (like NEXT) generated after ectodomain shedding, enabling γ-secretase substrate recognition.

APH-1 (anterior pharynx defective-1, APH1A or APH1B): A seven-pass transmembrane protein that scaffolds the complex and stabilizes presenilin.

PEN-2 (presenilin enhancer-2): A two-pass transmembrane protein required for presenilin endoproteolytic activation and for stabilizing the mature γ-secretase complex.

The γ-secretase complex performs sequential cuts: S3 cleavage releases NICD into the cytoplasm, while S4 cleavage (deeper within the TM helix) generates the Notch beta peptide — a short hydrophobic fragment that is cleared by SPPL2a/b (signal peptide peptidase-like proteases). NICD released by S3 cleavage retains the transcriptional activation machinery at its N-terminal RAM domain.

NICD Nuclear Function: CSL/RBPJ Transcriptional Switch

CSL/RBPJ: Context-Dependent Activator or Repressor

The primary transcriptional effector of Notch signaling is CSL (named for its homologues: CBF1/RBPJ in mammals, Suppressor of Hairless [Su(H)] in Drosophila, LAG-1 in C. elegans). RBPJ (recombination signal binding protein for Ig κ-J region) is a sequence-specific transcription factor that binds the consensus GTGGGAA motif. In the absence of NICD, RBPJ recruits a co-repressor complex including SHARP/MINT (SPEN family proteins), NCoR, HDAC1/3, and KDM5A (histone demethylase), maintaining Notch target genes in a repressed state. RBPJ thus functions as a signal-regulated switch: the same DNA-binding factor drives active repression in Wnt-off cells and active transcription in Notch-on cells.

NICD-CSL Ternary Complex Formation

NICD released by γ-secretase rapidly translocates to the nucleus. The NICD RAM domain (200 aa N-terminal to the ANK repeats) binds RBPJ with high affinity (Kd ~0.5 nM) at the β-trefoil domain of RBPJ — this is the highest-affinity interaction in the Notch-RBPJ system and dominates complex formation kinetics. The ANK (ankyrin) repeat domain of NICD then contacts the RBPJ Rel Homology Domain (RHD-C). Together, RAM and ANK engage RBPJ cooperatively, displacing co-repressors from RBPJ's C-terminal domain. A third component, MAML (Mastermind-like protein, MAML1/2/3), forms a ternary complex by bridging NICD-ANK and RBPJ, completing the transcriptional activation complex. The NICD-MAML-RBPJ ternary complex structure (Wilson and Bhatt, 2005; Nam et al., 2006) showed that MAML adopts an elongated helix that contacts both NICD-ANK and RBPJ simultaneously, with no direct DNA contacts — MAML functions as a transcriptional scaffold.

The assembled NICD-MAML-RBPJ complex recruits: p300/CBP (histone acetyltransferase), P-TEFb (CDK9/cyclin T, promoting RNA Pol II pause release), BRD4 (bromodomain protein at super-enhancers), and SEC (super elongation complex), driving chromatin remodeling and robust transcriptional activation at Notch-responsive promoters and enhancers.

HES and HEY Target Gene Families

The best-characterized Notch transcriptional targets are the bHLH repressor proteins of the HES (Hairy/Enhancer of Split) and HEYL/HEYV (HES-related with YRPW motif) families:

HES1: Direct Notch target with RBPJ sites in its promoter; HES1 protein auto-inhibits its own transcription (Hes1 oscillates with ~2 h period in many cell types via auto-repression delay), creating the Notch-driven transcriptional oscillator that controls somitogenesis clock and neural progenitor cycling. HES1 is a potent repressor of proneural genes (MATH1, NEUROG2, NEUROD1) and Notch ligands (DLL1, JAG1), executing lateral inhibition and maintaining neural progenitor identity.

HES5: Expressed in neural stem cells and oligodendrocyte precursors; activated by Notch in a less oscillatory, more sustained manner than HES1. HES5 suppresses neuronal and oligodendrocyte differentiation genes.

HEY1/HEY2/HEYL: HEY (hairy/enhancer-of-split related with YRPW motif) genes are particularly important in cardiovascular Notch signaling. HEY1 and HEY2 are induced by DLL4/Notch1 and JAG1/Notch signaling in arterial endothelium and smooth muscle. HEY2 is required for ventricular compaction and is a Notch1/2 target in trabecular myocardium specification.

NRARP: A small ankyrin repeat protein that destabilizes the NICD-MAML-RBPJ complex by competing with MAML for ANK domain binding — a direct negative feedback mechanism within the nucleus.

Lateral Inhibition and Inductive Notch Signaling

Lateral Inhibition: Neural Progenitor Fate

Lateral inhibition is the canonical Notch patterning mechanism in which a cell that adopts a primary fate actively suppresses the same fate in its neighbors. The circuit: a cell stochastically increases Notch ligand (DLL1/DLL4) expression → this activates NICD in neighbors → NICD-driven HES1 represses Notch ligand expression in neighbors → neighbors become ligand-low/receptor-high and remain undifferentiated while the original cell differentiates into the primary fate. This positive-feedback/lateral-inhibition circuit generates regularly spaced salt-and-pepper differentiation patterns (neural sensory cells in Drosophila notum, hair cells in inner ear, intestinal secretory cells from Atoh1+ progenitors).

Mathematical modeling and experimental validation (Collier et al., 1996) established that lateral inhibition requires both direct cell-cell contact (ruling out secreted morphogens) and a threshold response in ligand expression to Notch activation — features now attributable to HES1 auto-oscillation and DLL1 transcriptional regulation.

Inductive Notch Signaling: Vascular Arterial-Venous Specification

In contrast to symmetric lateral inhibition, inductive Notch signaling operates asymmetrically: a dedicated signal-sending cell type expresses Notch ligand and instructs adjacent signal-receiving cells to adopt a specific fate. The classic example is arterial endothelial specification:

Arterial identity requires DLL4/Notch1/4 signaling that induces EphB4 downregulation, EFNB2 (ephrin B2) upregulation, and expression of arterial markers (Connexin40/GJA5, NRP1, HEY1/HEY2). VEGF-A/VEGFR2 signaling upregulates DLL4 in presumptive arterial endothelium, creating a VEGF → DLL4 → Notch → arterial identity cascade. Venous identity is the default fate, maintained by COUP-TFII (NR2F2) transcription factor expression that suppresses Notch target genes in the venous endothelium.

Genetic evidence: Notch1/4 double knockout mice fail to remodel the primary vascular plexus and show arterial-venous malformations; endothelial NICD overexpression drives venous endothelium into an arterial identity. DLL4 heterozygous mice show dramatic hypersprouting and vascular hyperplasia — a finding that appears paradoxical until understood through the DLL4 → Notch → stalk cell suppression mechanism, where reduced DLL4 permits excess tip cell specification.

Non-Canonical Notch Signaling

Beyond the canonical NICD-RBPJ pathway, several non-canonical Notch mechanisms have been described:

Notch/NF-κB crosstalk: NICD physically interacts with IKKα and promotes NF-κB target gene expression in T-cell lymphoma and pancreatic cancer contexts, independent of RBPJ.

Notch/Wnt interaction: NICD can interact with LEF1 to promote Wnt target gene expression; alternatively, Notch-driven HES1 expression represses Nemo (IKKγ) to dampen Wnt-driven NF-κB in intestinal stem cells.

Cytoplasmic Notch: NOTCH1 ICD can interact with mTORC2 (via SIN1/RICTOR) to regulate AKT phosphorylation, connecting Notch to metabolic signaling independently of transcription.

Research Tools and Pharmacological Inhibitors

Experimental Protocols

Protocol 1: DAPT-Mediated Notch Pathway Inhibition — Dose-Response

Objective: Establish γ-secretase inhibitor potency on Notch target gene suppression and assess selectivity vs. γ-secretase APP/Aβ processing.

Materials: Jurkat T-ALL cells (high baseline NOTCH1 activity) or C2C12 myoblasts; DAPT (10 mM DMSO stock); LY411575 (1 mM stock); anti-cleaved Notch1 (Val1744, NICD antibody, Cell Signaling #4147); HES1 antibody; NICD (active Notch1) antibody (Cell Signaling #3608).

Protocol:

1. Seed 5 × 10⁵ Jurkat cells/mL; treat with DAPT (0, 0.01, 0.1, 1, 10 µM) or LY411575 (0, 0.001, 0.01, 0.1, 1 µM) for 24 h.

2. Western blot: lyse pellets in RIPA; 30 µg protein/lane; blot for cleaved NOTCH1 (Val1744), total NOTCH1, HES1, GAPDH.

3. qRT-PCR: extract RNA (RNeasy); measure HES1, HES5, HEY1, NRARP, MYC mRNA.

4. For selectivity: measure Aβ40/42 by ELISA from conditioned medium to assess APP γ-secretase cleavage at same DAPT concentrations (provides selectivity index: Notch IC₅₀/APP IC₅₀).

Expected results: DAPT IC₅₀ for NICD/HES1 suppression ~0.1–0.5 µM in Jurkat cells; LY411575 IC₅₀ ~0.5–5 nM; HES1 mRNA suppressed >80% at DAPT 1 µM; Aβ suppression occurs at similar or slightly lower concentrations, highlighting the challenge of Notch-sparing γ-secretase inhibitor development.

Protocol 2: Lateral Inhibition Assay in Neural Progenitor Cultures

Objective: Quantify Notch-mediated lateral inhibition using single-cell resolution tracking of fate commitment.

Materials: Embryonic cortical neural progenitors (E14.5 mouse) or human iPSC-derived NPCs; DLL1 and DLL4 lentiviral overexpression constructs; HES1-GFP reporter lentivirus; anti-TUJ1 (neuronal), anti-SOX2 (progenitor) antibodies; confocal microscope.

Protocol:

1. Dissociate cortical tissue with papain; plate at 5 × 10⁴/cm² on poly-ornithine/laminin-coated coverslips in neural maintenance medium.

2. Infect with HES1-GFP reporter (RBPJ-binding site → d2EGFP) at MOI 3 to visualize Notch activity at single-cell level.

3. Culture 48 h; add DAPT (5 µM) or vehicle. Image live cells every 30 min for 24 h (confocal timelapse, 10× objective).

4. At 48 h post-DAPT: fix, stain TUJ1 (neuron), SOX2 (progenitor), GFP.

5. Quantify: % GFP-high (Notch-active, progenitor) vs. GFP-low (Notch-inactive, differentiating) cells; DAPT treatment should increase % TUJ1+ neurons and reduce GFP-high cells, consistent with lateral inhibition release.

6. Compare neighbor-pair GFP levels (GFP-high cell adjacent to GFP-low cell at higher frequency than random → lateral inhibition signature).

Expected results: Vehicle: ~40–60% cells are GFP-high (Notch-active progenitors); DAPT (5 µM, 48 h): reduces GFP-high fraction to <20% and increases TUJ1+ neurons ~2-fold; live imaging reveals fate switching events where a GFP-high cell spontaneously becomes GFP-low within 2–4 h and begins neuronal morphology change.

Protocol 3: Vascular Tip/Stalk Cell Ratio Modulation by DLL4/Notch

Objective: Quantify DLL4/Notch-mediated stalk cell specification using HUVECs in a fibrin bead sprouting assay.

Materials: HUVECs (ATCC CRL-1730); cytodex-3 beads; fibrin gel (2.5 mg/mL fibrinogen + thrombin); MRC-5 feeder fibroblasts; VEGF165 (50 ng/mL); DLL4-Fc fusion protein (1–10 µg/mL); DAPT (5 µM); anti-ESM1 (tip cell marker); anti-NRP1 (arterial/tip marker).

Protocol:

1. Coat cytodex-3 beads with HUVECs (400 cells/bead); embed beads in fibrin gel in 24-well plates.

2. Overlay MRC-5 fibroblasts (20,000/well) as support layer; culture 7 days.

3. Day 0 treatment: VEGF165 (50 ng/mL) + vehicle, DAPT (5 µM), DLL4-Fc (5 µg/mL), or anti-DLL4 antibody (1 µg/mL).

4. Day 7: fix 4% PFA; stain F-actin (phalloidin), DAPI; image on confocal.

5. Quantify: sprout number/bead, sprout length, branching frequency, tip cell filopodial count.

6. For tip/stalk analysis: anti-ESM1 (tip cell marker) immunostaining; count ESM1+ tip cells per sprout.

Expected results: VEGF165 alone: 8–15 sprouts/bead, 2–4 branch points. DAPT (Notch blockade): increased sprout branching (+50–100% branch points), increased tip cell number (ESM1+ cells) — consistent with DLL4-Notch normally suppressing excess tip cell specification. DLL4-Fc: reduced sprouting, reduced ESM1+ tip cells — consistent with soluble DLL4 acting as competitive antagonist to clear endogenous DLL4/Notch receptor interactions.

Protocol 4: CSL/RBPJ Reporter Assay for Notch Transcriptional Activity

Objective: Quantify NICD-RBPJ transcriptional activity using a 4× CSL-binding site luciferase reporter.

Materials: 4×CSL-luciferase plasmid (4× tandem GTGGGAA RBPJ motif driving firefly Luc; available from Addgene, e.g., pGa981-6); pRL-TK Renilla; U2OS or HEK293T cells; ICN1 (Notch1 NICD) expression plasmid; DNMAML expression plasmid.

Protocol:

1. Transfect U2OS: 4×CSL-Luc (400 ng) + pRL-TK (40 ng) ± ICN1 (100–400 ng) ± DNMAML (200 ng) ± DAPT (5 µM post-transfection).

2. 36 h post-transfection: Dual-Luciferase assay.

3. For endogenous Notch activation: co-culture with DLL4-expressing cells (transfect HEK293T with DLL4 + GFP 24 h ahead; plate reporter U2OS on DLL4-HEK293T monolayer).

4. Quantify firefly/Renilla ratio; calculate fold-induction over empty vector + vehicle.

Expected results: ICN1 overexpression: 20–100-fold CSL-Luc induction dose-dependently; DNMAML co-expression suppresses ICN1-driven activation by >90% (validates MAML-dependence); DAPT (5 µM) reduces co-culture (DLL4-driven) activation by >80%; endogenous DLL4-co-culture induces ~5–15-fold activation.

Protocol 5: Notch1 Cleavage Product Detection by Sequential Immunoprecipitation

Objective: Biochemically distinguish S2-cleaved (NEXT) from S3-cleaved (NICD) Notch processing intermediates to map γ-secretase activity.

Materials: Notch1 ECD antibody (anti-NRR domain); anti-NICD (Val1744); anti-ECD (distinguishes uncleaved from S1-processed); HEK293T; MG132 (proteasome inhibitor to stabilize NICD); DAPT; GM6001 (broad ADAM metalloprotease inhibitor).

Protocol:

1. Treat cells with: vehicle, DAPT (5 µM, blocks S3 → accumulates NEXT), GM6001 (10 µM, ADAM inhibitor, blocks S2 → prevents NEXT/NICD), or MG132 (10 µM, stabilizes NICD).

2. Lyse in CHAPS buffer (1% CHAPS, 150 mM NaCl, 50 mM Tris pH 7.5) to preserve transmembrane interactions; 30 min 4°C; clarify.

3. Immunoprecipitate with anti-Notch1 C-terminal (intracellular domain) antibody.

4. Western blot eluate with: anti-NICD (Val1744, detects S3 product), anti-transmembrane proximal (detects NEXT), anti-full-length Notch1.

5. DAPT: expect NEXT accumulation (S2 but not S3 cleavage); GM6001: expect uncleaved Notch accumulation; MG132: expect NICD stabilization (longer t½).

Expected results: DAPT accumulates NEXT band (~110 kDa, detected by C-terminal antibody and absent Val1744 signal) 3–5-fold over vehicle; MG132 stabilizes NICD (~100 kDa, Val1744-positive) 5–10-fold; GM6001 prevents NEXT/NICD accumulation, blocking upstream of S2 — a clean biochemical demonstration of the sequential S2/S3 cleavage cascade.

Disease Relevance

T-Cell Acute Lymphoblastic Leukemia (T-ALL): NOTCH1 Gain-of-Function

NOTCH1 is the most frequently mutated gene in T-ALL (~60% of cases), with mutations clustered in two hotspot regions: (1) the NRR (HD domain mutations like L1601P destabilize NRR → ligand-independent S2 cleavage), and (2) the PEST domain (truncations that remove the degron → NICD accumulation). These mutations converge on producing ligand-independent NICD accumulation and constitutive HES1/c-Myc target gene activation. The translocation t(7;9)(q34;q34.3) placing ICN1 under TCRβ regulatory control is the founding oncogenic Notch lesion identified in the original T-ALL discovery (Ellisen et al., 1991).

γ-Secretase inhibitors (GSIs) suppress NOTCH1-driven proliferation in T-ALL cell lines but cause intestinal goblet cell metaplasia as an on-target toxicity — reflecting Notch's requirement for intestinal absorptive vs. secretory fate specification. This GI toxicity has driven interest in MAML-directed inhibitors (SAHM1) and Notch1 NRR-selective antibodies that spare intestinal Notch activity.

Alagille Syndrome: JAG1 Haploinsufficiency

Heterozygous loss-of-function mutations in JAG1 (70–94% of cases) or NOTCH2 (rare) cause Alagille syndrome — an autosomal dominant condition featuring bile duct paucity, peripheral pulmonary artery stenosis, characteristic facies, vertebral arch defects, and ocular posterior embryotoxon. JAG1-NOTCH2 signaling drives biliary differentiation from hepatoblasts during liver development; reduced JAG1 dosage shifts the hepatoblast fate toward hepatocytes at the expense of cholangiocytes.

Cerebral Autosomal Dominant Arteriopathy (CADASIL): NOTCH3 EGF Repeat Mutations

Missense mutations in EGF-like repeats 1–6 of NOTCH3 (causing unpaired cysteine residues) cause CADASIL — a cerebrovascular disease with stroke, dementia, and characteristic granular osmiophilic material (GOM) deposits in the perivascular space. The mutant NOTCH3 ECD is shed but not cleared, accumulating as aggregates in vessel walls and impairing vascular smooth muscle Notch3 signaling. CADASIL represents a unique disease mechanism where Notch3 ECD accumulation is toxic independent of NICD signaling — distinct from simple Notch loss-of-function.

Notch Crosstalk with Other Pathways Covered in This Series

Notch signaling intersects with multiple pathways detailed elsewhere in this peptide research guide series:

Wnt/β-catenin: In the intestinal crypt, Notch activation (Hes1 expression) suppresses Math1/Atoh1, preventing secretory fate and cooperating with Wnt to maintain LGR5+ stem cells. Pharmacological experiments: combined DAPT + IWP-2 treatment collapses organoid growth more completely than either alone.

EGF/EGFR: EGF receptor signaling promotes ADAM17-mediated Notch S2 cleavage (ligand-independent Notch activation) in several epithelial cancers, linking EGFR oncogenic signaling to Notch pathway activation.

BMP-2/SMAD: Notch and BMP compete for osteoblast specification. Hey1 (Notch target) binds and inhibits RUNX2, suppressing BMP-driven osteogenesis. Reduced Notch activity (by DAPT or DNMAML) enhances BMP-2-driven ALP upregulation in MSCs.

Summary

Notch signaling achieves spatial and temporal patterning precision through its contact-dependent, proteolysis-gated mechanism. Ligand endocytosis generates pulling force that exposes the Notch NRR to ADAM10-mediated S2 cleavage; γ-secretase then liberates NICD from the membrane; NICD-MAML-RBPJ ternary complex formation on CSL sites converts target genes from active repression to active transcription, primarily through HES1/HES5/HEY family bHLH repressors. Lateral inhibition (neural progenitor, intestinal secretory fate) and inductive signaling (arterial endothelial specification, T-cell development) exploit the same molecular mechanism at different scales and in different cellular geometries.

Research tools — from DAPT and DNMAML for pathway blockade to 4×CSL-luciferase reporters and HES1-GFP live imaging — provide orthogonal methods for dissecting Notch activity at every level of the signaling cascade. Disease contexts from T-ALL (NOTCH1 gain-of-function) to Alagille syndrome (JAG1 loss) and CADASIL (NOTCH3 EGF repeat mutations) demonstrate the pathway's breadth and establish clear therapeutic targets that are now being translated through γ-secretase inhibitor and antibody programs.

---

For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.

References

1. Artavanis-Tsakonas S, Rand MD, Lake RJ (1999). Notch signaling: cell fate control and signal integration in development. Science, 284(5415), 770–776. PMID: 10221902

2. Hellström M, et al. (2007). Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature, 445(7129), 776–780. PMID: 17259973

3. Gordon WR, et al. (2007). Structural basis for autoinhibition of Notch. Nature Structural & Molecular Biology, 14(4), 295–300. PMID: 17401372

4. Hartmann D, et al. (2002). The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Human Molecular Genetics, 11(21), 2615–2624. PMID: 12354787

6. Nam Y, et al. (2006). Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell, 124(5), 973–983. PMID: 16530044

7. Ellisen LW, et al. (1991). TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell, 66(4), 649–661. PMID: 1831692

8. Weng AP, et al. (2004). Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science, 306(5694), 269–271. PMID: 15472075

9. Joutel A, et al. (1996). Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature, 383(6601), 707–710. PMID: 8878478

10. Alagille D, et al. (1987). Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. Journal of Pediatrics, 110(2), 195–200. PMID: 3806290

11. Collier JR, et al. (1996). Pattern formation by lateral inhibition with feedback: a mathematical model of Delta-Notch intercellular signalling. Journal of Theoretical Biology, 183(4), 429–446. PMID: 9015458

12. Kopan R, Ilagan MX (2009). The canonical Notch signaling pathway: unfolding the activation mechanism. Cell, 137(2), 216–233. PMID: 19379690

13. Ables JL, et al. (2011). Notch1 is required for maintenance of the reservoir of adult hippocampal stem cells. Journal of Neuroscience, 31(17), 6408–6419. PMID: 21525281